Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640089 | 0.81 | PIK3CD (0.41) | KDM4EALDH1A1DRD2DRD3TP53 | |
| SCHEMBL27718315 | 0.79 | KDM4E (0.38) | KDM4EALDH1A1DRD2DRD3TP53 | |
| SCHEMBL13975261 | 0.79 | DRD2 (0.39) | KDM4EALDH1A1DRD2DRD3TP53 | |
| SCHEMBL17563249 | 0.78 | TYR (0.41) | KDM4EALDH1A1DRD2DRD3TP53 | |
| SCHEMBL18914245 | 0.76 | ALDH1A1 (0.39) | KDM4EALDH1A1DRD2DRD3APOBEC3A | |
| SCHEMBL21241923 | 0.76 | DRD2 (0.37) | KDM4EALDH1A1DRD2DRD3APOBEC3A | |
| SCHEMBL17563245 | 0.76 | ACACB (0.43) | KDM4EALDH1A1MAPTPOLBHTR2A | |
| SCHEMBL20705071 | 0.75 | HSP90AA1 (0.31) | HTR2AHTR2C | |
| SCHEMBL21201593 | 0.75 | MAPT (0.61) | TP53MAPTPOLB | |
| SCHEMBL1346009 | 0.75 | TYR (0.44) | KDM4EALDH1A1DRD2DRD3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| EP-3689863-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | KDM4E 2530/4885ALDH1A1 4181/4885DRD2 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.